Breaking News

Pluri’s CDMO to Manufacture Kadimastem’s Cell Therapy Candidates

PluriCDMO will manufacture AstroRx for the treatment of ALS for an upcoming Phase 2a study, and IsletRx for the treatment of diabetes.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pluri Inc., a biotechnology company, has signed a tech transfer and manufacturing agreement with Kadimastem Ltd., a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO, launched earlier this year, leverages Pluri’s 47,000 sq.-ft. GMP cell production facility to manufacture cell-based products for life science companies. PluriCDMO will manufacture two cell therapy candidates for Kadimastem: AstroRx, clinical grade human astrocytes (nerv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters